SOAPware, Inc. Introduces State-of-the-Art Patient Engagement Platform

FAYETTEVILLE, Ark., March 11, 2015 /PRNewswire/ -- SOAPware Inc., an electronic health record (EHR), has introduced myHEALTHware™: the complete solution to patient care coordination. 

myHEALTHware™ is a state-of-the-art healthcare tool that combines the best of social networking plus 20 years of medical software know-how resulting in a robust, feature-rich platform that delivers maximum privacy, security and ease-of-use.

myHEALTHware™ is the ultimate coordinated care solution, providing the tools and resources needed to view patient data, connect with healthcare professionals, coordinate with internal and external team members, communicate with other software users and much more.

The myHEALTHware™ system serves as a Health Information Service Provider (HISP), allowing users to connect and share files with other providers via the open-standard, HIPAA-compliant Direct Protocol, regardless of which EHR they use.

In addition, myHEALTHware™ also allows patients to easily manage their health information, providing secure access to medical records, a safe portal for sharing information with family, and reliable messaging with everyone in their medical network.

Thousands of patients and physicians across the country are now utilizing the innovative technology provided through myHEALTHware™.

For more information about myHEALTHware™, visit myhealthware.com or contact the SOAPware marketing department at ladonna.humphrey@soapware.com.

About SOAPware 

Founded by physicians, for nearly two decades SOAPware, Inc. has adhered to a simple philosophy of delivering affordable technology to healthcare providers. Improving healthcare and the quality of life by empowering medical professionals and patients with innovative technology and services, is the mission we are committed to achieve. To learn more about SOAPware, ranked #1 in Quality of Care by physicians all across the United States, visit www.SOAPware.com.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.